|Dr. William G. Rice||Chairman, Pres & CEO||898.83k||N/A||1959|
|Dr. Jotin Marango Ph.D., M.D.||Sr. VP, Chief Bus. & Strategy Officer and Interim CFO||573.66k||N/A||1979|
|Dr. Rafael Bejar M.D., Ph.D.||Sr. VP & Chief Medical Officer||566.92k||N/A||1972|
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Aptose Biosciences Inc.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 6; Compensation: 7.